Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.49 |
| ▸ | FEN1 | P39748 | 4/20 | 0.49 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 8/20 | 0.36 |
| ▸ | PRKX | P51817 | 1/20 | 0.36 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.36 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999402 | 1.00 | ALOX5AP (0.49) | ALOX5APFEN1DDR1ROCK2ROCK1 | |
| SCHEMBL2002014 | 1.00 | ALOX5AP (0.49) | ALOX5APFEN1DDR1ROCK2ROCK1 | |
| SCHEMBL2001180 | 0.88 | ALOX5AP (0.49) | ALOX5APFEN1ROCK2ROCK1PRKX | |
| SCHEMBL2001179 | 0.88 | ALOX5AP (0.49) | ALOX5APFEN1ROCK2ROCK1PRKX | |
| SCHEMBL2001317 | 0.88 | ALOX5AP (0.49) | ALOX5APFEN1ROCK2ROCK1PRKX | |
| SCHEMBL2003081 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1DDR1MMP2MMP13 | |
| SCHEMBL1998882 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1DDR1MMP2MMP13 | |
| SCHEMBL1998886 | 0.88 | ALOX5AP (0.45) | ALOX5APFEN1DDR1MMP2MMP13 | |
| SCHEMBL2001653 | 0.85 | ALOX5AP (0.46) | ALOX5APFEN1ROCK2ROCK1PRKX | |
| SCHEMBL2000923 | 0.85 | ALOX5AP (0.46) | ALOX5APFEN1ROCK2ROCK1PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | claimed |
| EP-1932841-B1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2014-01-01 | — | — | EP | disclosed |
| US-8415372-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2013-04-09 | — | — | US | disclosed |
| US-7964613-B2 | (S)-3-amino-1-(4-bromo-5-isoquinolinesulfonyl)pyrrolidine; inhibits phosphorylation of myosin regulatory light chain; for spinal canal stenosis, spinal cord injury, rheumatoid arthritis, multiple sclerosis; Rho kinase inhibitors | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20100093789-A1 | SULFONAMIDE COMPOUND | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-2130828-A1 | SULFONAMIDE DERIVATIVE | Asahi Kasei Pharma Corporation (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7618984-B2 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-20090048223-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1932841-A1 | SULFONAMIDE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2008-06-18 | — | — | EP | disclosed |
| US-20070179127-A1 | Sulfonamide compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093789-A1 | SULFONAMIDE COMPOUND | AKT1, ROCK1, ROCK2 | ALOX5AP 4150/4885FEN1 4212/4885DDR1 1191/4885 |
| US-20070179127-A1 | Sulfonamide compound | MYLK, MYLK2, MYLK3 | ALOX5AP 4520/4885FEN1 4586/4885DDR1 2523/4885 |
| US-20090048223-A1 | Sulfonamide compound | ALK, AKT1, ARAF | ALOX5AP 3609/4885FEN1 4520/4885DDR1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.